BORJE S ANDERSSON to Cell Line
This is a "connection" page, showing publications BORJE S ANDERSSON has written about Cell Line.
Connection Strength
0.147
-
Sensitivity of nucleotide excision repair-deficient human cells to ionizing radiation and cyclophosphamide. Anticancer Res. 2002 Jan-Feb; 22(1A):21-6.
Score: 0.029
-
Selection of a low antigenic variant subline from the TA3St ascites carcinoma by repeated passage of antibody-coated cells through anti-immunoglobulin columns. J Natl Cancer Inst. 1979 Aug; 63(2):383-8.
Score: 0.024
-
Doxorubicin analogues incorporating chemically reactive substituents. J Med Chem. 1991 Feb; 34(2):561-4.
Score: 0.014
-
Resistance to 4-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) in human myeloid leukaemia. Br J Cancer. 1990 Jan; 61(1):51-5.
Score: 0.013
-
Development and characterization of a human myelogenous leukemia cell line resistant to 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide. Cancer Res. 1987 Apr 01; 47(7):1897-904.
Score: 0.010
-
In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia. Cancer Res. 1987 Feb 15; 47(4):1040-4.
Score: 0.010
-
Ph-positive chronic myeloid leukemia with near-haploid conversion in vivo and establishment of a continuously growing cell line with similar cytogenetic pattern. Cancer Genet Cytogenet. 1987 Feb; 24(2):335-43.
Score: 0.010
-
Analysis of nuclear m-AMSA content by DNA fluorochrome competition. Eur J Cancer Clin Oncol. 1986 Jul; 22(7):883-9.
Score: 0.010
-
BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon. Oncogene. 1993 Jan; 8(1):101-9.
Score: 0.004
-
Alternative 5' end of the bcr-abl transcript in chronic myelogenous leukemia. Oncogene. 1989 Jan; 4(1):93-8.
Score: 0.003
-
Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line. Cancer. 1988 Sep 15; 62(6):1171-8.
Score: 0.003
-
Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genet Cytogenet. 1987 Aug; 27(2):349-56.
Score: 0.003
-
The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs. Biochem Biophys Res Commun. 1987 Apr 29; 144(2):787-93.
Score: 0.003
-
Diversity of the effect of recombinant tumor necrosis factors alpha and beta on human myelogenous leukemia cell lines. Blood. 1987 Mar; 69(3):721-6.
Score: 0.003
-
Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia. Cancer Res. 1986 Jul; 46(7):3330-3.
Score: 0.002
-
The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA). Biochem Biophys Res Commun. 1986 Jan 29; 134(2):638-45.
Score: 0.002
-
The c-abl, bcr and C lambda genes are amplified in a cell line but not in the uncultured cells from a patient with chronic myelogenous leukemia. Leuk Res. 1986; 10(12):1401-9.
Score: 0.002
-
Demonstration of natural antibodies in normal rabbit serum with similar specificity pattern as mouse natural killer cells. J Natl Cancer Inst. 1980 May; 64(5):1113-9.
Score: 0.002